<DOC>
	<DOCNO>NCT01388491</DOCNO>
	<brief_summary>This study conduct evaluate impact DR-102 , 28-day oral contraceptive compare standard 28-day oral contraceptive regimen hemostatic parameter healthy woman .</brief_summary>
	<brief_title>A Multinational Study Evaluate Effects 28-Day Oral Contraceptive Hemostatic Parameters Healthy Women</brief_title>
	<detailed_description />
	<mesh_term>Ethinyl Estradiol</mesh_term>
	<mesh_term>Estradiol</mesh_term>
	<mesh_term>Polyestradiol phosphate</mesh_term>
	<mesh_term>Desogestrel</mesh_term>
	<mesh_term>Hemostatics</mesh_term>
	<mesh_term>Contraceptives , Oral</mesh_term>
	<mesh_term>Estradiol 3-benzoate</mesh_term>
	<mesh_term>Estradiol 17 beta-cypionate</mesh_term>
	<mesh_term>Estradiol valerate</mesh_term>
	<mesh_term>Contraceptive Agents</mesh_term>
	<criteria>Premenopausal , nonpregnant , nonlactating woman age 1840 year old Body Mass Index ( BMI ) ≥18 kg/m² &lt; 30 kg/m² Regular spontaneous menstrual cycle Others dictate FDAapproved protocol Any condition contraindicates use combination oral contraceptives Any history , active , deep vein thrombosis , pulmonary embolism , arterial thromboembolic disease within one year screen Thrombophlebitis thromboembolic disorder ; know suspect clot disorder ; thrombogenetic valvulopathies rhythm disorder Others dictate FDAapproved protocol</criteria>
	<gender>Female</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>Contraception</keyword>
	<keyword>Hemostasis</keyword>
	<keyword>Blood Coagulation</keyword>
</DOC>